Navigation Links
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Date:7/18/2013

SOUTH SAN FRANCISCO, Calif., July 18, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases. 

Several new investors participated in the Series C financing, including the Topspin Fund, an investment group comprised of James Simons, Leo A. Guthart, Andy Gyenes and Steven Winick.  The financing also included participation from our existing investors, including The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures.  With the Series C financing, NGM has raised over $130 million since the company's founding in 2008.

"With this $50 million round of equity financing, coupled with non-dilutive capital from our collaborations with Daiichi Sankyo, Janssen, MedImmune and JDRF, NGM is well-positioned to advance the promising pipeline of candidates generated by our drug discovery efforts," said William J. Rieflin, Chief Executive Officer of NGM.  "We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases.  NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.  For more information, please visit the company's website at www.ngmbio.com.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
(Date:7/28/2014)... 28, 2014  Syneron Medical Ltd. (NASDAQ: ... today that its new PicoWay® device has received CE ... colors and pigmented lesions on any skin type. PicoWay ... 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay ... which are trillionths of a second, known as picosecond ...
(Date:7/28/2014)... July 28, 2014  ResMed (NYSE: RMD ... the treatment of sleep-disordered breathing and other chronic respiratory ... Germany against Taiwanese medical device manufacturer APEX ... on APEX WiZARD 210 and 220 masks.  The judgment ... Munich , is appealable, and applies throughout ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... of Obstetricians and Gynecologists (ACOG) and Society for ... and ensure that healthcare providers, patients, and the ...  The information update from ACOG and SMFM confirms ...
... MONTREAL, Oct. 13, 2011 A Medco Health Solutions, ... found that 38 percent of patients prescribed Plavix® (clopidogrel)—an ... and stroke—were also using another drug that would impede ... The analysis also showed that primary care physicians ...
Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4
(Date:7/28/2014)... Dennis Thompson HealthDay ... -- Babies born prematurely appear to have a slightly ... will carry into adulthood, Swedish researchers report. Doctors ... weeks, gestation have a raised risk of deep vein ... blood clotting in the veins, the researchers noted in ...
(Date:7/28/2014)... People with higher levels of brown fat have a ... suggests. Unlike white fat, which lowers insulin sensitivity, ... blood sugar control and fat-burning metabolism. "This is ... a professor of internal medicine in the division of ... at Galveston, said in a university news release. ...
(Date:7/28/2014)... study, published in the July, 2014, issue of ... by Northwestern Medicine researchers, sheds new light ... of endoscopic resection in the treatment of localized, ... traditional surgical resection, while more invasive, provided significantly ... rate for patients than endoscopic resection, which had ...
(Date:7/28/2014)... Smart phones and mobile devices are on the cusp ... apps capable of providing everything from cardiac measurements to ... to medical treatment and control costs, several health law ... of Medicine (NEJM) report that more oversight is ... to ensure consumer confidence and safety. Out of some ...
(Date:7/28/2014)... 2014 A young couple from a ... stories in the media today about parents accidentally leaving ... matter of minutes in a hot car. July 31 ... of Emergency Medical Services at NHTSA. , Shaun and ... Realizing that it’s all too easy to get distracted, ...
Breaking Medicine News(10 mins):Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2
... a method for male contraception that is effective, reversible ... new study accepted for publication in The Endocrine Society,s ... JCEM ). , "For couples who can not, ... have been limited to vasectomy, condom and withdrawal," said ...
... New England States, Enhancement of Health Coverage Programs ... from HealthLeaders-InterStudyNASHVILLE, Tenn., May 4 HealthLeaders-InterStudy, a ... that while Massachusetts, healthcare reform has been successful ... continue the program amid the recession and spiraling ...
... National child advocacy organization grades child health care reform ... days milestone, President Obama continues to enjoy high ratings ... his administration and 111th Congress score an "incomplete" for ... Monday by Voices for America,s Children, a premier national ...
... for organizations in SE Michigan . Event ... professionals. Increase wellness, decrease insurance costs, improve morale, ... 4 Cambridge Employee Benefits, a division of ... corporate Wellness & HR Summit May 21, 2009.The ...
... Prepared with Flu Preparedness Information from American Red CrossCHICAGO, ... are closing down due to the swine flu (H1N1 ... safe and reliable in-home caregiver options. In response ... a 20 percent discount to Sittercity.com for the month ...
... Month draws attention to urgency in preventing stroke and supporting 6 million ... ... -- This year nearly 795,000 people will have a stroke, leaving a ... according to National Stroke Association , which is observing National Stroke ...
Cached Medicine News:Health News:Massachusetts Healthcare Reform Cost Containment Strategy Featured in New Report 2Health News:Kids Group Scores Obama, Congress in 100 Days Report Card 2Health News:Cambridge Employee Benefits to Host Corporate Wellness & HR Summit 2Health News:In-Home Caregivers Standing by Nationwide to Support Increased Need Due to Swine Flu 2Health News:Four of Five Families Will Be Touched by Stroke in 2009 2
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... for LASIK surgery and other types of ... interface and/or stromal bed. Flattened tip provides ... elevate the flap edge. Multiple ports provide ... 22mm) Formed 9mm from end. Two .15mm ...
... for LASIK surgery and other types ... the corneal interface and/or stromal bed. ... the flap and helps elevate the ... irrigation. 21G x 7/8in (.80 x ...
Medicine Products: